The abstract is read at the publisher; the summary is JClub's.
cfDNA assays for early hepatocellular cancer detection show sensitivity that is noninferior or superior to ultrasound when combined with clinical and serum parameters.
- Why it matters: Current semiannual ultrasound with serum alpha-fetoprotein has suboptimal sensitivity and inconsistent implementation, limiting early-stage detection, while post-treatment monitoring is not tailored to tumor aggressiveness.
- What they did: This review summarizes recent cfDNA applications in hepatocellular cancer, highlighting early detection studies where cfDNA assays are integrated with clinical and serum measures, and noting larger phase 3 validation studies underway.
- The result: The evidence supports cfDNA’s strongest clinical momentum in early detection, while risk stratification, prognostication, and minimal residual disease assessment remain early and require multicenter standardized validation for routine use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.